Kura Oncology, Inc. (NASDAQ:KURA) is one of the shares Jim Cramer offered information on. When a caller highlighted the company’s $135 million milestone payment due to the commercial sale of KOMZIFTI in the United States, Cramer commented:
“That’s a lot. That’s a lot… Now, understand that, yes, these are milestone payments, not real ones. Now, here’s what you need to understand. I’ve always thought that if you have something that’s for cancer and it works, then you have to own the stock as a speculation, but only as a speculation, because it’s been a very difficult disease. J&J and Merck are the ones ahead if you want the big companies.”
Stock market reports printed on a sheet of paper. Photo by RDNE Stock Project on Pexels
Kura Oncology, Inc. (NASDAQ:KURA) is developing targeted cancer therapies focused on genetically defined leukemias and solid tumors, with several drug candidates in clinical development. In November, the company, along with Kyowa Kirin, received FDA approval for KOMZIFTI (ziftomenib), a once-daily targeted oral therapy for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. On December 8, Kura Oncology and Kyowa Kirin reported early trial results showing that KOMZIFTI combined with venetoclax and azacitidine was generally well tolerated and showed significant activity in AML with NPM1 mutations or KMT2A rearrangements. Gail J. Roboz, MD, hematologist and leukemia specialist (William S. Paley Professor of Clinical Medicine) said:
“In relapsed/refractory NPM1-m and KMT2A-r AML, overall response rates of 65% and 41% were observed, increasing to 83% and 70% in venetoclax-naïve patients, underscoring the potential benefit of ziftomenib even in difficult settings. Importantly, the inclusion of ziftomenib was generally well tolerated, paving the way for its integration into first-line regimens. and relapsed/refractory through ongoing registration testing.”
While we recognize KURA’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 30 stocks that should double in 3 years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published in Internal jumpsuit.